{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:50:09Z","timestamp":1792036209759,"version":"4.4.0"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCHTS"],"published-print":{"date-parts":[[2026,6,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Cyclophosphamide (CTX) is widely used in chemotherapy; however,\nits clinical application is frequently accompanied by gonadotoxic effects, which can result in impaired\novarian function and subsequent infertility in women. Consequently, effective strategies to\nmitigate chemotherapy-induced ovarian injury remain an important unmet need. Interleukin-35\n(IL-35), a recently identified member of the IL-12 cytokine family, has been implicated in immune\nregulation and the maintenance of immune homeostasis. In parallel, accumulating evidence\nindicates that ovarian damage involves multiple forms of regulated cell death rather than a single\napoptotic pathway. PANoptosis, an integrated cell-death program encompassing pyroptosis,\nnecroptosis, and apoptosis, has recently emerged as a key mechanism in tissue injury. To date,\nwhether IL-35 participates in CTX-induced ovarian injury and whether it modulates PANoptosisrelated\npathways has not been clearly elucidated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Female C57BL\/6 mice were randomly divided into four groups: control,\nCTX treatment, IL-35 treatment, and combined CTX + IL-35 treatment. Histopathological\nalterations in ovarian tissue were assessed using hematoxylin and eosin staining, whereas ELISA,\nqRT-PCR, immunohistochemistry, and western blot assays were subsequently conducted to\ninvestigate potential molecular mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>IL-35 showed a protective effect against CTX-induced ovarian injury. Serum FSH levels\nwere reduced. Serum E2 and AMH levels were increased. Ovarian histopathological structure\nwas improved. CTX treatment increased oxidative stress markers. These markers included ROS,\nSOD, and MDA. CTX treatment increased apoptosis markers (Bax and Bcl2). CTX treatment increased\npyroptosis markers (NLRP3 and IL-1\u03b2). CTX treatment increased necroptosis markers\n(p-MLK and p-RIPK1). IL-35 pretreatment reduced all listed molecular changes. Further analysis\nshowed enhanced activation of the ovarian Nrf2\/HO-1 signaling pathway after IL-35 pretreatment\nduring CTX exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>IL-35 preserves ovarian reserve during CTX challenge by activating Nrf2\/HO-1 to\nrestore redox balance, thereby coordinately inhibiting pyroptosis, necroptosis, and apoptosis-key\ndrivers of chemotherapy-induced follicular depletion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>IL-35 reduced CTX-induced ovarian injury. This effect occurs through the regulation\nof oxidative stress and PANoptosis. These findings indicate the therapeutic potential of IL-\n35 for ovarian injury caused by CTX.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0113862073467540260321183320","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T07:32:47Z","timestamp":1781249567000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Interleukin-35 Ameliorates Cyclophosphamide-induced Ovarian Injury by Inhibiting PANoptosis"],"prefix":"10.2174","volume":"29","author":[{"given":"Yuhan","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, The Second Affiliated Hospital, Jiangxi Medical College, NanchangUniversity, Nanchang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Jiangxi Key Laboratory of Molecular Medicine, The Second Affiliated Hospital, JiangxiMedical College, Nanchang University, Nanchang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Integrated Traditional Chinese and WesternMedicine, Nanchang Medical College, Nanchang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zhong","sequence":"additional","affiliation":[{"name":"Center for Reproductive Medicine, Jiangxi Maternal andChild Health Hospital, Jiangxi Branch of the National Clinical Research Center for Obstetrics and Gynecology,Nanchang Medical College, Nanchang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Center for Reproductive Medicine, Jiangxi Maternal andChild Health Hospital, Jiangxi Branch of the National Clinical Research Center for Obstetrics and Gynecology,Nanchang Medical College, Nanchang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The Second Affiliated Hospital, Jiangxi Medical College, NanchangUniversity, Nanchang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Combinatorial Chemistry &amp; High Throughput Screening"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113862073467540260321183320","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/254951\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113862073467540260321183320","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T07:32:50Z","timestamp":1781249570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/254951\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":0,"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113862073467540260321183320","relation":{},"ISSN":["1386-2073"],"issn-type":[{"value":"1386-2073","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2026-01-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}